Esperion Therapeutics has completed its acquisition of Corstasis Therapeutics, bringing the FDA-approved Enbumyst nasal spray into its cardiovascular portfolio. This first-in-class nasal spray loop diuretic helps manage fluid retention for congestive heart failure, marking a new step in Esperion’s plan to address the growing global burden of cardiometabolic disease. Executives anticipate that Enbumyst will bolster the company’s commercial capabilities and revenue growth.